Search results for " Angiogenesi"

showing 10 items of 70 documents

Assessing the Effects of VEGF Releasing Microspheres on the Angiogenic and Foreign Body Response to a 3D Printed Silicone-Based Macroencapsulation De…

2021

Macroencapsulation systems have been developed to improve islet cell transplantation but can induce a foreign body response (FBR). The development of neovascularization adjacent to the device is vital for the survival of encapsulated islets and is a limitation for long-term device success. Previously we developed additive manufactured multi-scale porosity implants, which demonstrated a 2.5-fold increase in tissue vascularity and integration surrounding the implant when compared to a non-textured implant. In parallel to this, we have developed poly(ε-caprolactone-PEG-ε-caprolactone)-b-poly(L-lactide) multiblock copolymer microspheres containing VEGF, which exhibited continued release of bioa…

RS1-441angiogenesisPharmacy and materia medicadiabetesmedical devicemulti-scale porositydiabetes; prevascularization; drug delivery; VEGF; medical device; multi-scale porosity; angiogenesisSettore BIO/10 - Biochimicadrug deliveryPharmaceutical ScienceprevascularizationVEGFArticlePharmaceutics
researchProduct

Patent number RM2009A000073: Procedimento di preparazione di scaffold polimerici preangiogenizzati

2009

Classe proposta A61F - Filtri da inserire nei vasi sanguigni; protesi; apparecchi ortopedici e curativi per contraccezione; fomentazione; trattamento o protezione degli occhi e delle orecchie; bendaggi, garze per medicazioni e assorbenti; necessario per il pronto soccorso

Settore ING-IND/24 - Principi Di Ingegneria ChimicaSettore ING-IND/22 - Scienza E Tecnologia Dei MaterialiSettore BIO/10 - BiochimicaScaffold Ingegneria tissutale polimeri biodegradabili angiogenesi
researchProduct

Down with the erythropoietin. Long live the erythropoietin!

2009

In recent years the use of erythropoietin has exploded, and the anaemia of patients with chronic renal failure has been practically resolved with the administration of rHuEpo (recombinant human, Erythropoietin). However, as a result of an intense commercial campaign, strong therapies with this growth hormone, prescribed to achieve surprising sporting performances, got athletes to run the risk of thrombosis and vascular accidents because of red blood cells increase. Erythropoietin represents a significant subject of research. In fact, besides the ability of stimulating erythrocyte production, it has many pleiotropic effects. Several studies allow the assertion that EPO, in different concentr…

Settore MED/09 - Medicina InternaAngiogenesisClinical BiochemistryCentral nervous systemUrodelaStimulationAthletic PerformanceBioinformaticsRegenerative MedicineRegenerative medicineDose-Response RelationshipKidney FailureDrug DiscoverymedicineErythropoietin NeuroprotectionAnimalsHumansChronicErythropoietinPharmacologyRecombinantDose-Response Relationship Drugbusiness.industrySettore MED/27 - NeurochirurgiaRegeneration (biology)CancerAnemiamedicine.diseaseRecombinant Proteinsmedicine.anatomical_structureAnemia Angiogenesis Inducing Agents Animals Athletic Performance Dose-Response Relationship; Drug Erythropoietin Erythropoietin; Recombinant Humans Kidney Failure; Chronic Regenerative Medicine UrodelaErythropoietinImmunologyMolecular MedicineKidney Failure ChronicAngiogenesis Inducing AgentsDrugbusinessmedicine.drugHormone
researchProduct

Synthesis of Fluorinated and Nonfluorinated Tebufenpyrad Analogues for the Study of Anti-angiogenesis MOA

2014

In this contribution we report the synthesis of fluorinated and nonfluorinated tebufenpyrad analogues to explore potential druglike properties through the phenotypic screening as part of the Lilly Open Innovation Drug Discovery (OIDD) program.

Tebufenpyradchemistry.chemical_compoundChemistryAnti angiogenesisStereochemistryDrug discoveryPhenotypic screeningOrganic ChemistryPhysical and Theoretical ChemistryCombinatorial chemistry
researchProduct

Ratios between VEGF ligands and receptors in tumor and stroma have impact on the outcome in resectable NSCLC.

2013

e22147 Background: In tumor angiogenesis there is a complex interplay between endothelial, stromal and tumor cells. Some key regulators of this process are the members of the vascular endothelial growth factor (VEGF) family of ligands and receptors and the neuropilins (NRP). This study analyzes the correlations between the expression of these angiogenic factors in tumor cells and tumor stroma, and their prognostic role in tissue samples from resected non-small cell lung cancer (NSCLC) patients. Methods: Representative tumor and stroma areas from FFPE tissue samples of 125 early-stage NSCLC patients were carefully micro-dissected. RNA isolated from the samples was retrotranscripted and prea…

Tumor angiogenesisCancer ResearchStromal cellbiologybusiness.industryVEGF receptorsTumor cellsOncologyStromabiology.proteinCancer researchMedicinebusinessReceptorJournal of Clinical Oncology
researchProduct

Recent advances on aptamer-based biosensors to detection of platelet-derived growth factor.

2018

Platelet-derived growth factor (PDGF-BB), a significant serum cytokine, is an important protein biomarker in diagnosis and recognition of cancer, which straightly rolled in proceeding of various cell transformations, including tumor growth and its development. Fibrosis, atherosclerosis are certain appalling diseases, which PDGF-BB is near to them. Generally, the expression amount of PDGF-BB increases in human life-threatening tumors serving as an indicator for tumor angiogenesis. Thus, identification and quantification of PDGF-BB in biomedical fields are particularly important. Affinity chromatography, immunohistochemical methods and enzyme-linked immunosorbent assay (ELISA), conventional m…

Tumor angiogenesisModels MolecularPlatelet-derived growth factorProtein biomarkersComputer scienceAptamerBiomedical EngineeringBiophysicsBecaplermin02 engineering and technologyComputational biologyBiosensing Techniques01 natural scienceschemistry.chemical_compoundElectrochemistryAnimalsHumansTumor growth010401 analytical chemistryGeneral MedicineElectrochemical TechniquesProto-Oncogene Proteins c-sisAptamers Nucleotide021001 nanoscience & nanotechnology0104 chemical sciencesBiomarker (cell)Serum cytokinechemistryLuminescent MeasurementsNanoparticlesColorimetry0210 nano-technologyBiosensorBiotechnologyBiosensorsbioelectronics
researchProduct

Integrin-dependent and -independent functions of astrocytic fibronectin in retinal angiogenesis

2011

Fibronectin (FN) is a major component of the extracellular matrix and functions in cell adhesion, cell spreading and cell migration. In the retina, FN is transiently expressed and assembled on astrocytes (ACs), which guide sprouting tip cells and deposit a provisional matrix for sprouting angiogenesis. The precise function of FN in retinal angiogenesis is largely unknown. Using genetic tools, we show that astrocytes are the major source of cellular FN during angiogenesis in the mouse retina. Deletion of astrocytic FN reduces radial endothelial migration during vascular plexus formation in a gene dose-dependent manner. This effect correlates with reduced VEGF receptor 2 and PI3K/AKT signalli…

Vascular Endothelial Growth Factor AIntegrinsAngiogenesisIntegrinNeovascularization PhysiologicMice TransgenicExtracellular matrixMicePhosphatidylinositol 3-KinasesCell MovementAnimalsProtein Interaction Domains and MotifsMolecular BiologyResearch ArticlesMice KnockoutSprouting angiogenesisbiologyRetinal VesselsCell migrationKinase insert domain receptorVascular Endothelial Growth Factor Receptor-2Extracellular MatrixFibronectinsCell biologyMice Inbred C57BLFibronectinVascular endothelial growth factor AAstrocytesbiology.proteinHeparitin SulfateOligopeptidesProto-Oncogene Proteins c-aktIntegrin alpha5beta1Signal TransductionDevelopmental BiologyDevelopment
researchProduct

Capillary enlargement, not sprouting angiogenesis, determines beneficial therapeutic effects and side effects of angiogenic gene therapy.

2010

Aims Currently, it is still unclear which mechanisms drive metabolic benefits after angiogenic gene therapy. The side-effect profile of efficient angiogenic gene therapy is also currently incompletely understood. In this study, the effects of increasing doses of adenoviral (Ad) vascular endothelial growth factor-A (VEGF-A) were evaluated on vascular growth, metabolic benefits, and systemic side effects. Methods and results Adenoviral vascular endothelial growth factor-A or AdLacZ control was injected intramuscularly (109–1011 vp/mL) or intra-arterially (5 × 1011 vp/mL) into rabbit ( n = 102) hindlimb muscles and examined 6 or 14 days later. Blood flow, tissue oedema, metabolic benefits, and…

Vascular Endothelial Growth Factor Amedicine.medical_specialtyAngiogenesisGenetic VectorsNeovascularization PhysiologicEnzyme-Linked Immunosorbent Assayta3111Injections IntramuscularAdenoviridaeNeovascularizationchemistry.chemical_compoundInternal medicinemedicineAnimalsMuscle SkeletalUltrasonography InterventionalSprouting angiogenesisDose-Response Relationship Drugbusiness.industryGene Transfer TechniquesMetabolic acidosisGenetic Therapymedicine.diseaseCapillariesHindlimbVascular endothelial growth factorVascular endothelial growth factor AEndocrinologychemistryLac OperonCirculatory systemRabbitsmedicine.symptomCardiology and Cardiovascular MedicinebusinessPerfusionEuropean heart journal
researchProduct

POOLED ESTIMATES OF INCIDENCE OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS WITH AND WITHOUT TOPI…

2017

Purpose: To assess the effect of topical antibiotic prophylaxis on postoperative endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.Methods: A systematic literature search was performed from inception to March 2016 using PubMed, Medline, Web of Science, Embase, and the Cochrane Library, to identify articles that reported cases of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. We used a pooled analysis to estimate the incidence of cases of endophthalmitis who developed after injections performed with and without topical antibiotic prophylaxis. We used regression analysis to explore the effects of stu…

Vascular Endothelial Growth Factor Amedicine.medical_specialtyEye InfectionsVisual AcuityAntibiotic prophylaxis; Anti–vascular endothelial growth factor; Endophthalmitis; Intravitreal injection;Angiogenesis InhibitorsCochrane LibraryGlobal HealthEye Infections Bacteriallaw.invention03 medical and health sciencestopical antibiotic prophylaxis; postoperative endophthalmitis; anti–vascular endothelial growth factor agents; intravitreal injectionpostoperative endophthalmitis0302 clinical medicineEndophthalmitisRandomized controlled triallawtopical antibiotic prophylaxisanti–vascular endothelial growth factor agentsInternal medicinemedicineantibiotic prophylaxiHumansanti-vascular endothelial growth factor030212 general & internal medicineAntibiotic prophylaxisProspective cohort studyAntibiotic prophylaxis; Anti–vascular endothelial growth factor; Endophthalmitis; Intravitreal injection; Angiogenesis Inhibitors; Anti-Bacterial Agents; Endophthalmitis; Eye Infections Bacterial; Global Health; Humans; Intravitreal Injections; Vascular Endothelial Growth Factor A; Antibiotic Prophylaxis; Visual AcuityEndophthalmitisbusiness.industryIncidence (epidemiology)Bacterialintravitreal injectionRetrospective cohort studyGeneral MedicineEye infectionAntibiotic Prophylaxismedicine.diseaseAntibiotic prophylaxis; Anti–vascular endothelial growth factor; Endophthalmitis; Intravitreal injection; Angiogenesis Inhibitors; Anti-Bacterial Agents; Endophthalmitis; Eye Infections; Bacterial; Global Health; Humans; Intravitreal Injections; Vascular Endothelial Growth Factor A; Antibiotic Prophylaxis; Visual AcuitySurgeryAnti-Bacterial AgentsOphthalmologyendophthalmitiIntravitreal Injections030221 ophthalmology & optometryAnti–vascular endothelial growth factorbusiness
researchProduct

VEGF-B as a target for cancer therapy : characterization of monoclonal antibodies towards VEGF-B and generation of VEGF-B expressing tumour cell lines

2007

Vascular Endothelial Growth Factor Btumour angiogenesismonoclonal antibody therapysyöpävasta-aineetVEGF-B
researchProduct